MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/hae.70326

Медицинская библиотека · Haemophilia : the official journal of the World Federation of Hemophilia · 2026

Optimizing Perioperative Management of Haemophilia B With rFIX-FP: Pharmacokinetic Validation of the Hemoptidose Tool.

Delavenne Xavier, Vollard Célia, Drillaud Nicolas, Castet Sabine, Luyck Nicolas, Hénin Emilie, Seve Julien Denis-Le, Volot Fabienne, Tardy Brigitte, Désage Stéphanie, Guillet Benoît

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Surgical management of haemophilia B requires precise factor IX replacement to ensure adequate haemostasis while optimizing factor consumption. Extended half-life rFIX-FP simplifies perioperative management but exhibits substantial pharmacokinetic variability. PK-guided dosing is recommended by WFH guidelines, yet validated tools for perioperative rFIX-FP individualization are lacking.

OBJECTIVES

To validate a population PK model under perioperative conditions and evaluate Hemoptidose, a model-informed precision dosing (MIPD) platform, for individualizing rFIX-FP therapy during surgery.

METHODS

We retrospectively analyzed 24 surgeries in haemophilia B patients treated with rFIX-FP. Predictive performance was assessed at population level and after Bayesian individualization with varying numbers of FIX samples. Actual perioperative consumption was retrospectively compared with Hemoptidose-recommended doses.

RESULTS

The population PK model demonstrated robust perioperative performance. Population predictions yielded a mean absolute error (MAE) of 20.6%; after Bayesian updating, accuracy improved with MAE of 10.0%. Prediction error decreased from 20.6% without monitoring to 14% with three samples. Retrospective analysis indicated a potential 49% reduction in factor consumption with model-guided dosing compared to empirical regimens (p < 0.001).

CONCLUSIONS

The population PK model retains valid predictive performance in surgical settings. Two to three FIX measurements enable reliable individualization. The substantial discrepancy between empirical and model-guided dosing highlights major optimization potential. Hemoptidose provides accessible MIPD implementation for perioperative rFIX-FP management.

Для цитирования: Delavenne Xavier, Vollard Célia, Drillaud Nicolas, Castet Sabine, Luyck Nicolas, Hénin Emilie, Seve Julien Denis-Le, Volot Fabienne, Tardy Brigitte, Désage Stéphanie, Guillet Benoît. Optimizing Perioperative Management of Haemophilia B With rFIX-FP: Pharmacokinetic Validation of the Hemoptidose Tool.. Haemophilia : the official journal of the World Federation of Hemophilia. 2026. DOI: 10.1111/hae.70326.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.